Peregrine shares spike on Ph2 cancer data

Shares of Peregrine Pharmaceuticals ($PPHM) spiked 20% this morning after the company reported that advanced and metastatic breast cancer patients taking a combination of bavituximab and docetaxel experienced a median survival rate of 20.7 months in a prior single arm Phase II study involving 46 patients. Release

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.